Across TCGA pan-cancer cohorts, MTHFS Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MTHFS data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MTHFS Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MTHFS expression acts as an unfavorable survival marker.
HNSC, COAD, and SARC are the cancer types where MTHFS Mutation most reproducibly stratifies survival.